http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
View Older Stories
-
KemPharm (KMPH) Promotes Sven Guenther to Chief Scientific Officer, Christal Mickle to Chief Product Development Officer
-
KemPharm Announces Promotion of Sven Guenther, Ph.D., to Chief Scientific Officer and Christal Mickle, M.A., to Chief Product Development Officer
-
KemPharm (KMPH) Announces Board and Leadership Changes
-
KemPharm Announces Board and Leadership Changes to Support its Transformation into a Leading Rare Disease Company
-
KemPharm Announces Initiation of Phase 2 Clinical Trial Investigating KP1077 for the Treatment of Idiopathic Hypersomnia (IH)
-
KemPharm (KMPH) Announces Appointment of Christopher Posner as New Independent Director
-
KemPharm Announces Appointment of Christopher Posner as New Independent Director
-
KemPharm (KMPH) Granted FDA Orphan Drug Designation for Serdexmethylphenidate
-
KemPharm Receives FDA Orphan Drug Designation for Serdexmethylphenidate (SDX) for the Treatment of Idiopathic Hypersomnia (IH)
-
KemPharm Reports Third Quarter 2022 Results
-
KemPharm to Report Third Quarter 2022 Financial Results
-
KemPharm Supports Niemann-Pick Awareness Month During October and Global Niemann-Pick Awareness Day on October 19th
-
KemPharm (KMPH) Reports Positive Topline Data from Phase 1 Clinical Trial Evaluating Cardiovascular Safety of Serdexmethylphenidate
-
KemPharm Announces Positive Topline Data from Phase 1 Clinical Trial Evaluating Cardiovascular Safety of Serdexmethylphenidate (SDX)
-
KemPharm to Present at the H.C. Wainwright 24th Annual Global Investment Conference
-
KemPharm Reports Second Quarter 2022 Financial Results and Corporate Updates
-
KemPharm Appoints Nichol Ochsner as Vice President, Investor Relations and Corporate Communications
-
KemPharm to Report Second Quarter 2022 Financial Results
-
KemPharm to Present at the Canaccord Genuity 42nd Annual Growth Conference
-
KemPharm to Participate in the 2022 Joint NNPDF-INPDA Conference and Meeting
-
KemPharm (KMPH) Reports Research Affirming Serdexmethylphenidate’s Lower Potential for Abuse
-
KemPharm Announces Research Affirming Serdexmethylphenidate’s Lower Potential for Abuse Featured in Peer-Reviewed Publication, Current Medical Research & Opinion
-
KemPharm (KMPH) Acquires Arimoclomol from Orphazyme
-
KemPharm Announces Strategic Acquisition of Arimoclomol from Orphazyme, Expanding its Rare CNS Diseases Pipeline
-
KemPharm to Present at Multiple Upcoming Investor Conferences
-
KemPharm (KMPH) Submits IND of Phase 2 Trial of KP1077 in Idiopathic Hypersomnia
-
KemPharm Announces Submission of Investigational New Drug Application for Phase 2 Trial of KP1077 in Idiopathic Hypersomnia (IH)
-
KemPharm to Report First Quarter 2022 Financial Results
-
KemPharm Doses First Subject in Phase 1 Clinical Trial Evaluating Cardiovascular Safety of Serdexmethylphenidate (SDX)
-
KemPharm Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Corporate Updates
-
KemPharm to Participate in Maxim’s 2022 Virtual Growth Conference
-
KemPharm (KMPH) Reports Full Data Set from Higher-Dose Serdexmethylphenidate (SDX) Phase 1 Clinical Trial
-
KemPharm Announces Full Data Set from Higher-Dose Serdexmethylphenidate (SDX) Phase 1 Clinical Trial
-
KemPharm (KMPH) Earns $1.975 Million Fee from Corium Following FDA Approval of the Corium Product ADLARITY
-
KemPharm Earns $1.975 Million Fee from Corium Following FDA Approval of the Corium Product ADLARITY® (donepezil transdermal system)
-
KemPharm to Report Fourth Quarter and Full-Year 2021 Results
-
KemPharm (KMPH) Successfully Completes KP1077 Pre-IND Meeting Process with FDA
-
KemPharm Completes KP1077 Pre-IND Meeting Process with FDA
-
KemPharm (KMPH) Issues Letter to Shareholders Detailing Strategic Focus on CNS/Rare Disease Indications and Updated Clinical Development Strategy
-
KemPharm Issues Letter to Shareholders Detailing Strategic Focus on CNS/Rare Disease Indications and Updated Clinical Development Strategy
-
KemPharm to Host Investor Conference Call Detailing Plans for Pipeline Expansion
-
KemPharm Announces Research Involving Serdexmethylphenidate to be Featured in Two Poster Presentations at the APSARD 2022 Annual Conference
-
KemPharm to Participate in BIO Partnering @ JPM During “J.P. Morgan Week 2022”
-
KemPharm (KMPH) Announces $50M Share Buyback
-
KemPharm, Inc. Announces Authorization of $50 Million Share Repurchase Program
-
KemPharm (KMPH) Announces Top-Line Results from Clinical Trial Evaluating the Safety and Pharmacokinetics of “Higher-Dose SDX
-
KemPharm, Inc. Announces Top-Line Results from Clinical Trial Evaluating the Safety and Pharmacokinetics of “Higher-Dose SDX”
-
KemPharm (KMPH) to be Added to the Nasdaq Biotechnology Index Effective December 20
-
KemPharm to be Added to the Nasdaq Biotechnology Index Effective December 20, 2021
-
KemPharm Named 2021 David J. Gury Company of the Year by BioFlorida
